Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Prof/Dr. Nagi Kumar received her PhD in 1992 from the University of South Florida, her RD in 1982 from City Hospital Center at Elmhurst, Mt. Sinai School of Medicine in New York, and is a clinical Registered Dietitian and Fellow of the American Dietetic Association. She is a senior member of the H. Lee Moffitt Cancer Center and Research Institute, and currently the Director for Cancer Chemoprevention. Her clinical and research interest for the past two decades has focused on cancer chemoprevention, treatment and symptom management strategies targeting high risk and cancer patient populations. Her research group was the first to demonstrate android obesity at diagnosis was a risk factor as well as a poor prognostic indicator for survival from breast cancer. That group then focused on systematically examining the role of obesity, body mass index, body composition, body fat distribution, timing of weight gain, implications on steroid hormones and breast and endometrial cancer risk and prognosis. Founded on the observations of increased risk for recurrence as a result of android obesity at diagnosis, and observation of weight gain, lethargy and fatigue reported in breast cancer patients on chemotherapy, they were the first to report potential effects of subclinical hypothyroidism in this cohort. They are now evaluating the role of subclinical hypothyroidism as a physiological basis for fatigue in a cohort of breast cancer patients post chemotherapy compared to age-matched controls. By forging collaborations with investigators in basic, population and clinical sciences, she has laid the foundation to develop a program towards identification and evaluation of the safety, effectiveness and the underlying mechanisms of botanicals, biologics and other agents with a known safety profile in the prevention, treatment of cancers and to provide interventions, both therapeutic and lifestyle that carry the potential to treat or ameliorate late effects of cancer treatments. Using a multi-disciplinary science-based approach and the rigor test other therapeutic agents, she has initiated several epidemiological, laboratory, preclinical and phase I-II clinical trials evaluating safety, effectiveness and potential molecular targets of several agents including isoflavones, lycopene, green tea polyphenols, tannic acid, n-3 fatty acids, metformin, anthocyanin’s, curcumin and combination agents for cancer prevention, in addition to multimodal interventions to characterize and ameliorate symptoms of hypothyroidism, cancer cachexia and cognitive impairment. Dr. Kumar serves on the NIH/NCI/CDP Chemo/Dietary Prevention Study Section, a member of the NIH/NCI/P01 Study Section Panel, DOD-Congressionally Directed Medical Research Program (CDMRP) Prostate Cancer (PCRP) Study Section, member of the PDQ Cancer Complementary and Alternative Medicine Editorial Board of the NCI/NIH, and member of the advisory board of the Indo-US Cooperation in Life Sciences (Cancer Botanical Drug Development)/NIH. Dr. Kumar has authored more than 70 research articles, numerous book chapters, and in 2012 published a book entitled “Nutritional Management of Symptoms of Cancer Treatment Effects”.
Cancer chemoprevention, Treatment and symptom management strategies targeting high risk and cancer patient populations.